Screen Reader Access   

People : Scientific : Faculty & Scientists


Research Scientist D
+91-129-2876310  (+91-129-6525527)
mohan [at] thsti [dot] res [dot] in
Ph.D., Jamia Hamdard University, Delhi.
M.Sc. (Virology), Sri Venkateswara University, Tirupati.

Present Research Interests

Research Areas:

Currently available Adenoviral vectors are either not suitable for use in humans due to the toxicity issues associated with some of these vector or are protected under IPRs. So, my major objective is to identify animal Adenovirus isolates from field samples and investigate their use as novel gene/vaccine delivery vehicles in humans and animals. In this direction, we have isolated adenovirus isolates from samples collected from domestic birds and animals. Our current efforts are focused on the molecular and bioinformatic characterization of fowl, bovine and porcine adenovirus isolates and development of novel delivery vectors based on these isolates. Also, as part of our efforts to investigate the potential of animal adenovirus-based vectors as gene/vaccine delivery vehicles, we are currently investigating the vaccine delivery potential of an Ovine adenovirus recombinant expressing a highly antigenic protein derived from a human viral pathogen.

Besides, among infectious diseases, I had been working in the field of vaccine and therapeutic development against flaviviral diseases. For the development of potential vaccines or therapeutics, it is important to understand in detail the different immunological/viral pathways during the course of viral infection and disease. Vascular endothelium plays an important role in pathogenesis during flavivirus infections and disruption/ dysfunction of endothelium membrane is positively associated with disease severity. Although a role for pro-inflammatory cytokines has been shown in this process, sequence of events leading to this outcome is not known. Additionally, some of the studies have demonstrated a facilitatory role for the extracellular vesicles in affecting the endothelial permeability. The questions that I ask are whether EVs play a role in the induction of compromised epithelium and what are the mechanisms by which the effector molecules induce barrier disruption during JEV/DENV infections.

Also, recently we have developed and patented a novel DNAzyme-based therapeutic molecule against JEV and demonstrated its potential in vivo. However, lack of efficient systems for their in vivo expression and targeted delivery are the major roadblocks that hinder exploitation of their true therapeutic potential. Accordingly, part of my current work is focused in these areas for the development of clinically compatible and viable DNAzyme-based therapies against Flavivirus diseases.

  • Appaiahgari MB and Vrati S. (2015) Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther, 15(3): 337-351
  • Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, Mishra S, Vrati S. (2014) Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine, 32(6):651-656.
  • Chandola TR, Taneja S, Goyal N, Rathore SS, AppaiahgariMB, (2013). Descriptive epidemiology of rotavirus infection in a community in North India. Epidemiol Infect, 141(10): 2094-2100.
  • Gupta S, Dudha N, AppaiahgariMB, Bharati K, (2012). Molecular cloning and characterization of Chikungunya virus genes from Indian isolate of 2006 outbreak. J Pharm Res, 5(7): 3860-63.
  • AppaiahgariMB andVrati S (2012). Clinical developmentof IMOJEV® - a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin Biol Ther, 12(9): 1251-63.
  • Appaiahgari MB and Vrati S (2010). IMOJEV®: A Yellow Fever Virus-based novel Japanese Encephalitis Vaccine. Expert Rev Vaccines, 9(12): 1371-1384.
  • Appiahgari MB, Abdin MZ, Bansal KC and Vrati S (2009). Expression of Envelope (E) protein of Japanese encephalitis virus in transgenic tobacco. J Virol Meth,162(102): 22-29.
  • Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, Appaiahgari MB, Mishra A, Singh S, Vrati S, Rotavirus Vaccine Development Group (2009). A dose-escalation safety and immunogenicity study of Live attenuated Oral Rotavirus vaccine 116E in infants: A randomized, double-blind, placebo-controlled trial. J Infect Dis, 200: 421-429.
  • Appaiahgari MB, Pandey RM and Vrati S (2007). Seroprevalence of Neutralizing antibodies to Adenovirus 5 in Indian children: Implications for recombinant Adenovirus-based vaccines. Clin Vac Immunol, 14: 1053-55.
  • Appaiahgari MB and Vrati S (2007). DNAzyme-mediated inhibition of Japanese encephalitis virus replication in Mouse brain. Mol Ther, 15: 1593-99.
  • Bhowmick S, Duseja R, Das S, Appaiahgiri MB, Vrati S, Basu A (2007). Induction of IP-10 (CXCL10) in astrocytes following Japanese encephalitis. Neuroscience let, 414: 45-50.
  • Appaiahgari MB, Saini M, Rauthan M, Jyoti and Vrati S (2006) Immunization with recombinant Adenovirus synthesizing the secretory form of Japanese Encephalitis virus envelope protein protects Adenovirus-exposed mice against lethal encephalitis. Microbes Infect, 8 (1): 92-104.
  • Kaushik Bharati, Appaiahgari MB and Vrati S (2005) Effect of Cytokine-encoding plasmid delivery on immune response to Japanese Encephalits virus DNA vaccine in mice. Short comm. Microb. Immunol, 49 (4): 349-53.
  • Rauthan M, Kaur R, Appaiahgari MB and Vrati S (2004) Oral immunization of mice with Japanese Encephalitis virus envelope protein synthesized in Escherichia coli induces anti-viral antibodies. Microbes Infect, 6 (14): 1305-11.
  • Kabilan L, Vrati S, Ramesh S, Srinivasan S, Appaiahgari MB, Arunachalam N, Thenmozhi V, Kumaravel SM, Samuel PP and Rajendran R (2004) Japanese Encephalitis virus (JEV) is an important casue of encephalitis among children in Cuddalore district, Tamil Nadu, India. J. Clin. Virol, 31 (2): 153-9.
  • Appaiahgari MB and Vrati S (2004) Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese Encephalitis virus grown in Vero cells. Vaccine, 22 (27-28): 3669-75.

1.             Appaiahgari MB (2017), Plant-Based Edible Vaccines: Issues and Advantages. In: Plant Biotechnology: Principles and Applications. P 329-366. Eds. Abdin MZ, Usha Kiran, Kamaluddin & Athar Ali. ISBN: 978-981-10-2959-2 (Print) 9780981-10-2961-5 (Online) Springer International Publishing AG – Part of Springer Nature.

  1. European patent application (EP1833966), 2007.                          DNAzymes for inhibition of Japanese Encephalitis virus replication.       Inventors: Vrati S & Appaiahgari MB.  Status: Published / Claims being examined
  2. Australian patent application (AU2005315143), 2007.                    DNAzymes for inhibition of Japanese Encephalitis virus replication.     Inventors:Vrati S & Appaiahgari MB.  Status: Granted on 08.11.2011
  3. US patent application (11/721596), 2007.                                      DNAzymes for inhibition of Japanese Encephalitis virus replication.                    Inventors: Vrati S & Appaiahgari MB.  Status: Published / Claims being examined
  4. Singapore patent application # 133150.                       DNAzymes for inhibition of Japanese Encephalitis virus replication.       Inventors: Vrati S & Appaiahgari MB.  Status: Granted on 30.04.2012
  5. PCT application (WO/2006/06519), 2006.                                     DNAzymes for inhibition of Japanese encephalitis virus replication.        Inventors: Vrati S & Appaiahgari MB.  Status: Published / Claims Accepted
  6. Indian patent application (2482/DEL/2004).                            DNAzymes for inhibition of Japanese Encephalitis virus replication.       Inventors: Vrati S & Appaiahgari MB.  Status: Published / Exam. requested
  7. Indian patent application (1130/DEL/2003).                                Vaccine for Japanese Encephalitis and its process thereof.                    Inventors: Vrati S & Appaiahgari MB.  Status:Published / Exam. Requested

Received VRI Award from the Department of Biotechnology (DBT) for the year 2008